Literature DB >> 19756947

Contrast-enhanced ultrasonography (CEUS) immediately after percutaneous ablation of hepatocellular carcinoma.

A Gallotti1, M D'Onofrio, A Ruzzenente, E Martone, R De Robertis, A Guglielmi, R Pozzi Mucelli.   

Abstract

PURPOSE: This study evaluated the effectiveness of contrast-enhanced ultrasound (CEUS), performed immediately after percutaneous ethanol injection (PEI) or radiofrequency thermal ablation (RFTA), by comparing results with the computed tomography (CT) follow-up.
MATERIALS AND METHODS: Sixty-nine consecutive patients with a diagnosis of hepatocellular carcinoma (HCC) were included in this prospective study. All patients underwent PEI or RFTA. After treatment, three CEUS enhancement patterns were observed: isovascular, hypovascular and avascular, which were compared with the CT findings. Sensitivity of the avascular pattern at CEUS and effectiveness of the ablative procedures were evaluated and compared with the chi-square test.
RESULTS: Ninety hypervascular HCCs, with a mean diameter of 2.6 cm (0.5-4.9 cm), underwent PEI (n=54) and RFTA (n=36). In the first group, CT identified complete necrosis in 28/54 (52%) lesions, 21 (75%) of which had avascular, one (4%) isovascular and six (21%) hypovascular patterns at CEUS. In the second group, CT showed complete necrosis in 31/36 (86%) lesions, all (100%) of which had a corresponding avascular pattern at CEUS. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of the avascular pattern at CEUS compared with CT findings were 75%, 69%, 72%, 72% and 72% for PEI and 100%, 20%, 89%, 100% and 89%, for RFTA, respectively. A statistically significant difference (p<0.05) between the sensitivity of CEUS after PEI and after RFTA and between the necrosis obtained by RFTA and PEI were observed.
CONCLUSIONS: CEUS performed immediately after percutaneous ablation of hepatocellular carcinoma to evaluate treatment efficacy is compulsory in the case of RFTA but not for PEI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756947     DOI: 10.1007/s11547-009-0436-0

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  31 in total

Review 1.  Percutaneous radiofrequency thermal ablation of liver malignancies: techniques, indications, imaging findings, and clinical results.

Authors:  R Lencioni; D Cioni; C Bartolozzi
Journal:  Abdom Imaging       Date:  2001 Jul-Aug

Review 2.  Targeting portal pressure measurements: a critical reappraisal.

Authors:  Ulrich Thalheimer; Maria Mela; David Patch; Andrew K Burroughs
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

Review 3.  Image-guided tumor ablation: standardization of terminology and reporting criteria.

Authors:  S Nahum Goldberg; Clement J Grassi; John F Cardella; J William Charboneau; Gerald D Dodd; Damian E Dupuy; Debra Gervais; Alice R Gillams; Robert A Kane; Fred T Lee; Tito Livraghi; John McGahan; David A Phillips; Hyunchul Rhim; Stuart G Silverman
Journal:  Radiology       Date:  2005-04-21       Impact factor: 11.105

4.  Percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma.

Authors:  S Shiina; K Tagawa; T Unuma; A Terano
Journal:  AJR Am J Roentgenol       Date:  1990-05       Impact factor: 3.959

Review 5.  Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma.

Authors:  R Lencioni; C Della Pina; C Bartolozzi
Journal:  Abdom Imaging       Date:  2005 Jul-Aug

6.  Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; T Ierace; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

Review 7.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

8.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

Authors:  Shi-Ming Lin; Chun-Jung Lin; Chen-Chun Lin; Chao-Wei Hsu; Yi-Cheng Chen
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

9.  Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.

Authors:  J Bruix; A Castells; J Bosch; F Feu; J Fuster; J C Garcia-Pagan; J Visa; C Bru; J Rodés
Journal:  Gastroenterology       Date:  1996-10       Impact factor: 22.682

Review 10.  Strategies for the management of hepatocellular carcinoma.

Authors:  Myron Schwartz; Sasan Roayaie; Manousos Konstadoulakis
Journal:  Nat Clin Pract Oncol       Date:  2007-07
View more
  10 in total

Review 1.  Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy.

Authors:  Ping Liang; Jie Yu; Ming-De Lu; Bao-Wei Dong; Xiao-Ling Yu; Xiao-Dong Zhou; Bing Hu; Ming-Xing Xie; Wen Cheng; Wen He; Jian-Wen Jia; Guo-Rong Lu
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  [Contrast-enhanced sonography. Therapy control of radiofrequency ablation and transarterial chemoembolization of hepatocellular carcinoma].

Authors:  E M Jung; W Uller; C Stroszczynski; D-A Clevert
Journal:  Radiologe       Date:  2011-06       Impact factor: 0.635

3.  Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pre-treatment CECT/CEMRI after radiofrequency ablation for liver cancers.

Authors:  Xiao-Wan Bo; Hui-Xiong Xu; Le-Hang Guo; Li-Ping Sun; Xiao-Long Li; Chong-Ke Zhao; Ya-Ping He; Bo-Ji Liu; Dan-Dan Li; Kun Zhang; Dan Wang
Journal:  Br J Radiol       Date:  2017-07-27       Impact factor: 3.039

4.  Diagnostic accuracy of contrast-enhanced ultrasound in assessing the therapeutic response to radio frequency ablation for liver tumors: systematic review and meta-analysis.

Authors:  Min Xuan; Fengsheng Zhou; Yan Ding; Qiaoying Zhu; Ji Dong; Hao Zhou; Jun Cheng; Xiao Jiang; Pengxi Wu
Journal:  Surg Endosc       Date:  2017-12-21       Impact factor: 4.584

5.  Image-guided tumor ablation: emerging technologies and future directions.

Authors:  Justin P McWilliams; Edward W Lee; Shota Yamamoto; Christopher T Loh; Stephen T Kee
Journal:  Semin Intervent Radiol       Date:  2010-09       Impact factor: 1.513

6.  Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma.

Authors:  Yang Hai; Esika Savsani; Weelic Chong; John Eisenbrey; Andrej Lyshchik
Journal:  Abdom Radiol (NY)       Date:  2021-08-19

7.  Hepatocellular carcinoma after ablation: the imaging follow-up scheme.

Authors:  Lin-Na Liu; Hui-Xiong Xu; Yi-Feng Zhang; Jun-Mei Xu
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 8.  Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound.

Authors:  Shu-Guang Zheng; Hui-Xiong Xu; Lin-Na Liu
Journal:  World J Radiol       Date:  2014-01-28

9.  Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: clinical impact and health technology assessment.

Authors:  Giovanni Mauri; Emanuele Porazzi; Luca Cova; Umberto Restelli; Tania Tondolo; Marzia Bonfanti; Anna Cerri; Tiziana Ierace; Davide Croce; Luigi Solbiati
Journal:  Insights Imaging       Date:  2014-02-22

10.  Clinical significance of performing Sonazoid-based contrast-enhanced ultrasonography before ablation of uterine fibroids by high-intensity focused ultrasound: A preliminary cohort study.

Authors:  Lu Zhang; Tae Hee Kim; Kun Zhou; Lifeng Ran; Wei Yang; Hui Zhu
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.